Modulation of Hypoxia-Induced Chemoresistance to Polymeric Micellar Cisplatin: The Effect of Ligand Modification of Micellar Carrier Versus Inhibition of the Mediators of Drug Resistance

被引:15
作者
Abyaneh, Hoda Soleymani [1 ]
Soleimani, Amir Hassan [1 ]
Vakili, Mohammad Reza [1 ]
Soudy, Rania [1 ,2 ]
Kaur, Kamaljit [1 ,3 ]
Cuda, Francesco [4 ]
Tavassoli, Ali [4 ]
Lavasanifar, Afsaneh [1 ,5 ]
机构
[1] Univ Alberta, Fac Pharm & Pharmaceut Sci, Edmonton, AB T6G 2E1, Canada
[2] Cairo Univ, Fac Pharm, Cairo 11562, Egypt
[3] Chapman Univ, Sch Pharm, Irvine, CA 92618 USA
[4] Univ Southampton, Sch Chem, Southampton SO17 1BJ, Hants, England
[5] Univ Alberta, Fac Engn, Dept Chem & Mat Engn, Edmonton, AB T6G 1H9, Canada
关键词
hypoxia-induced chemoresistance; cisplatin; polymeric micelle; EGFR-targeted therapy; STAT3; HIF-1; GE11; peptide; pharmacological Inhibitors of HIF-1 and STAT3; combination therapy; GROWTH-FACTOR RECEPTOR; TARGETED DELIVERY; CANCER-CELLS; NANOPARTICLES; ACTIVATION; STAT3; EGFR; NANOTECHNOLOGY; IDENTIFICATION; CONJUGATION;
D O I
10.3390/pharmaceutics10040196
中图分类号
R9 [药学];
学科分类号
100702 [药剂学];
摘要
Hypoxia can induce chemoresistance, which is a significant clinical obstacle in cancer therapy. Here, we assessed development of hypoxia-induced chemoresistance (HICR) against free versus polymeric cisplatin micelles in a triple negative breast cancer cell line, MDA-MB-231. We then explored two strategies for the modulation of HICR against cisplatin micelles: a) the development of actively targeted micelles; and b) combination therapy with modulators of HICR in MDA-MB-231 cells. Actively targeted cisplatin micelles were prepared through surface modification of acetal-poly(ethylene oxide)-poly(alpha-carboxyl-epsilon-caprolactone) (acetal-PEO-PCCL) micelles with epidermal growth factor receptor (EGFR)-targeting peptide, GE11 (YHWYGYTPQNVI). Our results showed that hypoxia induced resistance against free and cisplatin micelles in MDA-MB-231 cells. A significant increase in micellar cisplatin uptake was observed in MDA-MB-231 cells that overexpress EGFR, following surface modification of micelles with GE11. This did not lead to increased cytotoxicity of micellar cisplatin, however. On the other hand, the addition of pharmacological inhibitors of key molecules involved in HICR in MDA-MB-231 cells, i.e., inhibitors of hypoxia inducing factor-1 (HIF-1) and signal transducer and activator of transcription 3 (STAT3), substantially enhanced the cytotoxicity of free and cisplatin micelles. The results indicated the potential benefit of combination therapy with HIF-1 and STAT3 inhibitors in overcoming HICR to free or micellar cisplatin.
引用
收藏
页数:18
相关论文
共 55 条
[1]
Hypoxia Induces the Acquisition of Cancer Stem-like Phenotype Via Upregulation and Activation of Signal Transducer and Activator of Transcription-3 (STAT3) in MDA-MB-231, a Triple Negative Breast Cancer Cell Line [J].
Abyaneh, Hoda Soleymani ;
Gupta, Nidhi ;
Alshareef, Abdulraheem ;
Gopal, Keshav ;
Lavasanifar, Afsaneh ;
Lai, Raymond .
CANCER MICROENVIRONMENT, 2018, 11 (2-3) :141-152
[2]
STAT3 but Not HIF-1 Is Important in Mediating Hypoxia-Induced Chemoresistance in MDA-MB-231, a Triple Negative Breast Cancer Cell Line [J].
Abyaneh, Hoda Soleymani ;
Gupta, Nidhi ;
Radziwon-Balicka, Aneta ;
Jurasz, Paul ;
Seubert, John ;
Lai, Raymond ;
Lavasanifar, Afsaneh .
CANCERS, 2017, 9 (10)
[3]
Nanoparticles for Targeting Intratumoral Hypoxia: Exploiting a Potential Weakness of Glioblastoma [J].
Aldea, Mihaela ;
Florian, Ioan Alexandru ;
Kacso, Gabriel ;
Craciun, Lucian ;
Boca, Sanda ;
Soritau, Olga ;
Florian, Ioan Stefan .
PHARMACEUTICAL RESEARCH, 2016, 33 (09) :2059-2077
[4]
Nanoparticles in the clinic [J].
Anselmo, Aaron C. ;
Mitragotri, Samir .
BIOENGINEERING & TRANSLATIONAL MEDICINE, 2016, 1 (01) :10-29
[5]
Stat3 is tyrosine-phosphorylated through the interleukin-6/glycoprotein 130/Janus kinase pathway in breast cancer [J].
Berishaj, Marjan ;
Gao, Sizhi Paul ;
Ahmed, Simi ;
Leslie, Kenneth ;
Al-Ahmadie, Hikmat ;
Gerald, William L. ;
Bornmann, William ;
Bromberg, Jacqueline F. .
BREAST CANCER RESEARCH, 2007, 9 (03)
[6]
Brahimi-Horn M., 2006, Bull Cancer, V93, P73
[7]
A cellular Trojan horse for delivery of therapeutic nanoparticles into tumors [J].
Choi, Mi-Ran ;
Stanton-Maxey, Katie J. ;
Stanley, Jennifer K. ;
Levin, Carly S. ;
Bardhan, Rizia ;
Akin, Demir ;
Badve, Sunil ;
Sturgis, Jennifer. ;
Robinson, J. Paul ;
Bashir, Rashid ;
Halas, Naomi J. ;
Clare, Susan E. .
NANO LETTERS, 2007, 7 (12) :3759-3765
[8]
Modeling and comparison of dissolution profiles [J].
Costa, P ;
Manuel, J ;
Lobo, S .
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2001, 13 (02) :123-133
[9]
Nanoparticle therapeutics: an emerging treatment modality for cancer [J].
Davis, Mark E. ;
Chen, Zhuo ;
Shin, Dong M. .
NATURE REVIEWS DRUG DISCOVERY, 2008, 7 (09) :771-782
[10]
Triple-Negative Breast Cancer [J].
Foulkes, William D. ;
Smith, Ian E. ;
Reis-Filho, Jorge S. .
NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (20) :1938-1948